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ABSTRACT
Objective: The aim of this study was to find the association of postprandial blood glucose with hypercoagulability in comparison to fasting blood 
sugars(FBS) in diabetic and healthy patients.
Methods: The present study involved a total of 156 patients, of which 78 were taken as cases (diabetics) and other 78 as controls (non-diabetics). 
Laboratory analysis included prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen assay done along with fasting, and 
postprandial sugars.
Results: Platelets in diabetics and healthy controls were in normal range. Decrease in PT and partial thromboplastin time was noted in diabetics 
compared to non-diabetic controls. Fibrinogen levels were increased in cases compared to controls. Changes in PT values were more significant with 
postprandial blood sugar (PPBS) levels when compared to FBS levels, and APTT follows the same pattern with more in PPBS levels and FBS levels in 
diabetics. PPBS showed elevated fibrinogen when compared to FBS in diabetics as well as non-diabetics.
Conclusion: Type 2 diabetes mellitus is a hypercoagulable state as proven by the following results of our study.
Keywords: Hypercoagulation, Fibrinogen levels, Clotting factors, Diabetes mellitus.
INTRODUCTION
Diabetes is chronic disease which is reaching an epidemic proportion in 
many parts of the world. Diabetes mellitus (DM) is a metabolic disorder 
characterized by elevated blood glucose levels and disturbances in 
carbohydrates, fats, and protein metabolism. Type 2 DM (T2DM) 
accounts for more than 90% of the diabetic population worldwide [1,2]. 
Both genetic and environmental factors are important in the 
development of the disease. The International Diabetes Federation 
estimates showed that 194 million people had diabetes in 2003 and it is 
expected to reach 333 million by the year of 2025 [1].
30 years ago, the prevalence of diabetes in India based on the Indian 
Council of Medical Research multicentric survey was around 2% in 
urban India and 1% in rural India. In just three decades, these prevalence 
rates have shot up to 12-16% in urban India and 3-8% in rural India, 
in adults over 20 years of age. These represent a 600-800% increase 
in prevalence rates of diabetes something which is unparalleled to any 
Western nation. Indeed, India is now referred to as the “diabetic capital” 
of the world.
Patients with diabetes are notorious for their risk of vascular events. 
Apart from the effects of diabetes and its prerequisite hyperglycemia on 
the development of atherosclerosis, this high risk may also be caused 
by the procoagulant state found in diabetes [3,4]. Type 2 diabetes is 
associated with a markedly increased risk for atherosclerotic coronary 
arteries and cerebrovascular diseases. Cardiovascular disease (CVD) 
remains the main cause of morbidity and mortality in individuals with 
diabetes. Up to 80% of diabetes, patients die because of cardiovascular 
complications, and the risk of atherothrombotic events in this 
population is similar to non-diabetic individuals with a history of 
ischemic heart disease (IHD) [3,5]. Moreover, the prognosis in these 
individuals following an event remains poor, despite major advances in 
treatment. Increased atherothrombotic risk is even evident in the pre-
diabetes stage as patients with insulin resistance and normoglycemia 
are at risk of cardiovascular events secondary to clustering of risk 
factors [4].
The underlying mechanisms for increased thrombosis risk in diabetes 
are complex and involve multiple pathways. Patients with diabetes 
have premature atherosclerosis and more extensive vascular disease, 
predisposing them to plaque rupture and thrombus formation [6]. In 
addition, these individuals have increased thrombotic tendency due 
to platelet hyperreactivity and increased activation of prothrombotic 
coagulation factors coupled with decreased fibrinolysis [7].
In recent years, hyperglycemia per se, even without overt diabetes, 
has gained interest as a potential target to improve clinical outcomes 
in hospitalized patients with acute illness [8]. In addition, there 
is evidence that abnormalities during the postprandial state, 
specifically postprandial hyperglycemia, are independent risk 
factors for atherosclerosis. Recent epidemiological studies suggest 
postprandial hyperglycemia is an independent risk factor for CVD 
that has effects greater than that of fasting hyperglycemia [9,10]. In 
this setting, the effects of hyperglycemia on the coagulation system 
may be of greater importance than previously considered. Hence, the 
aim of this study was to find the association of postprandial blood 
glucose with hypercoagulability in comparison to fasting blood 
sugars (FBS) in diabetic and healthy patients. Hence, the aim is to 
study the coagulation parameters in patients with T2DM, to compare 
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the obtained results with the control group (non-diabetic healthy 
controls), to study the relationship of coagulation parameters 
with fasting plasma glucose, and also to find the association of 
postprandial blood sugar with fibrinogen in comparison to FBS in 
diabetics.
METHODS
Outpatients attending Kasturba Hospital, Manipal, during the 
study period from November 2012 to August 2014, were screened 
and those who fulfilled the below mentioned inclusion criteria 
were selected. Others were excluded. This was a cross-sectional 
study. Cases were selected from outpatients attending Kasturba 
Hospital, Manipal, who were recently detected with DM based on 
the American Diabetes Association criteria. Controls were selected 
from our patients attending Kasturba Hospital, Manipal, with no 
history of DM or hypertension or IHD who were age and sex matched 
to the cases. The present study involved a total of 156 patients, of 
which 78 were taken as cases (diabetics) and other 78 as controls 
(non-diabetics) according to inclusion and exclusion criteria. Those 
patients who gave written consent for the study and fulfilled the 
inclusion and exclusion criteria were included in this study.
Inclusion criteria
Patients >30 years of age diagnosed to have T2DM. Patients with T2DM 
are not on treatment. Healthy controls who are matching diabetic 
patients
Exclusion criteria
The exclusion criteria were as follows: Type 1 diabetes and steroid-
induced DM. Patients with known hypercoagulable disorders. 
Patients on anticoagulants. Patients in renal failure, liver disease and 
multiple organ dysfunction syndrome, and sepsis. History of alcohol 
consumption and smoking.
Investigations
FBS was sample collected in sugar vacutainer, after overnight fasting of 
8 hrs, samples area analyzed by hexokinase method. Postprandial blood 
sugar (PPBS) sample was collected in sugar vacutainer after 2 hrs of 
taking meal and done by hexokinase method. Prothrombin time (PT) 
sample was collected in sugar citrated tubes and done by mechanical 
method. Activated partial thromboplastin time (APTT) sample was 
collected in sugar citrated tubes and done by mechanical method. 
Fibrinogen was collected in sugar sodium citrate buffer and done by 
density analyzer. Glycated hemoglobin sample was collected in sugar 
ethylenediaminetetraacetic acid tubes and done by chromatography. 
PT, APTT, and fibrinogen done along with fasting and postprandial 
sugars on the same day.
Statistical analysis
Data were obtained and analyzed using SPSS 16 version software. 
p<0.05 was taken as significant and was measured using Student 
paired t-test for the FBS and PPBS and PT, APTT, and fibrinogen. 
Analysis for adjusted sugar levels was done using Wilcoxon signed-rank 
test after adjusting for blood glucose levels by maintaining at least 
40 mg/dl difference between FBS and PPBS in both diabetics and 
controls. Pearson’s correlation coefficient was used to find the 
correlation between fibrinogen and FBS, PPBS.
RESULTS
Sex distribution
In diabetic patients, of the total 78, a number of male patients were 
63 (81%) and female patients were 15 (19%). In non-diabetic patients, 
of the total 78, a number of male patients were 62 (79%) and female 
patients were 15 (21%) (Fig. 1).
Age and body mass index (BMI)
The mean age of the patients in diabetic group was 52.474±10.327 years 
and in non-diabetic group was 52.436±8.960 years. The mean BMI 
in diabetic group was 24.561±2.652 and in non-diabetic group was 
23.389±2.406 (Table 1).
Blood pressure
The mean systolic blood pressure in diabetic group was 
129.026±11.499 mmHg and in non-diabetic group was 
128.692±16.356 mmHg. The mean diastolic blood pressure in diabetic 
group was 81.897±8.128 mmHg and in non-diabetic group was 
83.769±6.477 mmHg (Fig. 2).
Blood counts in diabetics and non-diabetics
The mean of hemoglobin in diabetic group was 14.007±1.299 and in 
non-diabetic group was 13.945±0.996 (Fig. 3). The mean platelet count 
in diabetic group was 259576.9±62238.444 and in non-diabetic group 
was 290192.3±54976.041 (Fig. 4). The mean total leukocyte count in 
diabetic group was 7037.179±1787 and in non-diabetic group was 
7235.128±1652.874 (Fig. 5).
Liver function tests
In both diabetic and non-diabetic group liver enzymes, aspartate 
transaminase, alanine transaminase, and alkaline phosphatase were 
within normal limits (Table 2).
Serum creatinine level
The mean serum creatinine level in diabetic group was 0.888±0.194 
and in non-diabetic group was 0.772±0.152 (Fig. 6).
Lipid profile
In diabetic group, total cholesterol, triglyceride, and low-density 
lipoprotein levels were elevated when compared to non-diabetic group. 
There was significant difference in triglyceride level in diabetic and 
non-diabetic group with p<0.01. The high-density lipoprotein levels 
were elevated in non-diabetic group when compared to the diabetic 
group p<0.001 (Table 3 and Fig. 7).
Fig. 1: Sex distribution in diabetics and non-diabetics
Fig. 2: Mean blood pressure in cases and controls
Table 1: Age and body mass index in diabetics and non-diabetics
Mean Diabetics Non-diabetics
Age of patients 52.474±10.327 52.436±8.960
Body mass index 24.561±2.652 23.389±2.406
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Glycated hemoglobin
The mean glycated hemoglobin level in diabetic group was 9.274±2.28 
and in non-diabetic group was 5.550±0.445 with p=0.001 (Fig. 8).
Blood sugar
In diabetic group, the mean of FBS was 184.09±64.52 and the mean of 
postprandial blood sugar was 265.52±78.00 (Fig. 9). In the non-diabetic 
group, the mean of FBS was 89.62±8.9 and mean of postprandial blood 
sugar was 121.41±10.18 (Fig. 10).
Fasting PT/APTT
The mean fasting PT in diabetic group was 15.01±1.95 seconds and in 
non- diabetic group was 15.30±1.23 seconds with (p=0.04) (Fig. 11). 
The mean fasting APTT in diabetic group was 30.57±4.17 seconds 
and in non-diabetic group was 32.10±4.16 seconds with (p=0.02) 
(Fig. 12).
Fasting fibrinogen assay
The mean fasting fibrinogen level in diabetic group was 
356.37±126.95 and in non-diabetic group was 282.95±63.47 
(p=0.01) (Fig. 13).
Fig. 3: Mean hemoglobin values
Fig. 4: Mean platelet counts
Fig. 5: Mean total leukocyte count
Fig. 6: Mean serum creatinine level
Fig. 7: Lipid profile analysis
Fig. 8: Glycated hemoglobin level





AST: Aspartate transaminase, ALT: Alanine transaminase, ALP: Alkaline 
phosphatase






Ratio of total cholesterol/HDL 4.67±1.49 4.07±1.46
HDL: High-density lipoprotein, LDL: Low-density lipoprotein
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PT in fasting and postprandial blood sugars in diabetics/non-
diabetics
In the diabetic group, the mean fasting PT was 15.01±1.95 seconds and 
the mean postprandial prothrombin time was 13.95±1.01 seconds with 
p=0.04. In non-diabetic group, the mean fasting PT was 15.30±1.23 
seconds and the mean postprandial PT was 15.10±1.07 seconds with 
p=0.686 (Figs. 14 and 15).
APTT in fasting and postprandial blood sugars in diabetics/non-
diabetics
In the diabetic group, the mean fasting activated thromboplastin 
time was 30.57±4.17 seconds and mean postprandial activated 
thromboplastin time was 29.32±5.10 seconds with p=0.02. In non-
diabetic group, the mean fasting activated thromboplastin time was 
32.10±4.16 seconds and mean postprandial activated thromboplastin 
time was 30.91±4.04 seconds with p=0.1 (Figs. 16 and 17).
Fibrinogen in fasting and postprandial blood sugars in diabetics/
non-diabetics
In diabetic group, the mean fasting fibrinogen assay was 356.37±126.95 
and the mean postprandial fibrinogen assay was 374.45±130.49 with 
p=0.001. In non-diabetic group, the mean fasting fibrinogen assay 
was 282.95±63.47 and mean postprandial fibrinogen assay was 
306.95±66.67 with p=0.002. Pearson’s correlation is given in table. In 
diabetics, fibrinogen correlation with PPBS is r=0.3, when compared 
to FBS r=0.2, and in non-diabetics, fibrinogen correlation with PPBS is 
r=0.1, when compared to FBS r=0.08 (Figs. 18-20 and Table 4).
Significance was found in adjusted blood sugars for fibrinogen between 
fasting and PPBS in both diabetics and non-diabetics (Table 5).
DISCUSSION
DM is associated with an increased risk of atherosclerosis, hence 
considered as a procoagulant state. Few studies are available evaluating 
coagulation screening tests in diabetes. In the present study, we aim 
to investigate coagulation parameter changes in diabetes and the 
Fig. 9: Fasting and postprandial blood sugar in diabetics
Fig. 10: Fasting and postprandial blood glucose in non-diabetics
Fig. 11: Prothrombin time in diabetics versus non-diabetics
Fig. 12: Activated partial thromboplastin time in diabetics versus 
non-diabetics
Fig. 13: Free fibrinogen assay in diabetics versus non-diabetics
Fig. 14: Fasting and postprandial prothrombin time in diabetic 
patients
Fig. 15: Fasting and postprandial prothrombin time in 
non-diabetics
382
Asian J Pharm Clin Res, Vol 10, Issue 7, 2017, 378-384
 Kadiyala et al. 
Fig. 16: Fasting and postprandial activated partial thromboplastin 
time in diabetics
Fig. 17: Fasting and postprandial activated partial thromboplastin 
time in non-diabetics
Fig. 18: Fasting and postprandial free fibrinogen assay in 
diabetics
association of PPBS with hypercoagulability as compared to FBS. The 
diabetic patients and healthy controls were age and sex matched. In the 
present study, the mean age of the diabetics was 52.47±10.32 years and 
healthy controls was 52.43±8.9 years. The male-to-female ratio was 4:1 
in both the diabetic and non-diabetic groups.
The mean BMI in diabetes was 24.56±2.65 and in healthy controls 
was 23.38±2.4. The platelet count was normal in the diabetic patients, 
i.e., there is no quantitative change compared to the non-diabetic 
population [3]. Platelet counts have been found to be normal in studies 
done by Borsey et al. [11] and Erem et al. [12]. In the study done by 
Madan et al., [13] diabetics have normal platelets counts similar to 
the present study where platelets in diabetics and healthy controls 
were in normal range (Table 6). Hyperglycemia directly contributes to 
endothelial injury through irreversible glycation of collagen and other 
subendothelial structural proteins of the vessel, forming advanced 
glycation end products [14] and endothelial dysfunction, can lead to 
an activated state characterized, in part, by increased platelet adhesion 
and aggregations [15].
Very few reports are available regarding coagulation screening tests in 
diabetes. The previous studies which were done for coagulation tests 
in diabetics and healthy controls were done in fasting state. Metabolic 
syndrome and T2DM patients have increased Factor VII (FVII) levels 
which can lead to decrease in PT [3,4]. Increased levels of TF in T2DM 
patients activate Factor VII and changed into VIIa. Activated Factor VII 
(VIIa) triggers the extrinsic pathway of coagulation through converting 
to Xa. In the study done by Acang and Jalil [16] showed decreased PT in 
diabetics when compared to healthy controls, similar results shown in 
the present study (p<0.05) (Table 7). The Factor VIII/vWF complex is 
also increased in individuals with insulin resistance and T2DM (4, 52, 
59, 61), which leads to decrease in APTT. The study done by Zhao 
et al. [17] showed significant difference in APTT in diabetics and controls 
being decreased APTT in diabetics when compared to healthy controls, 
similar results were obtained in the present study (p=0.02) (Table 8). 
Fibrinogen, another acute phase reactant, is increased in diabetics 
[4,18,19]. An increase in plasma fibrinogen levels is also considered an 
independent risk factor for CVD [20]. The effect of hyperglycemia on the 
Fig. 19: Fasting and postprandial free fibrinogen assay in 
non-diabetics
Fig. 20: Pearson’s correlation for fibrinogen levels and 
postprandial blood sugar in diabetics versus non-diabetics
Table 4: Pearson’s correlation for fibrinogen levels in diabetics 
versus non-diabetics
Correlation Diabetic fibrinogen Non-diabetic fibrinogen
FBS r=0.2 r=0.08
PPBS r=0.3 r=0.1
PPBS: Postprandial blood sugar, FBS: Fasting blood sugars
Table 5: Adjusted blood sugar levels
Mean DM Healthy controls 
Fasting fibrinogen 371.15±156.21 285.3±44.66
Postprandial fibrinogen 396.8±155.96 305.3±44.56
p 0.001 0.001
DM: Diabetes mellitus
Table 6: Comparison of platelet counts between the present 
study and previous studies
Mean Diabetics (platelet counts) Non-diabetics
Madan et al. 2.02±0.61 2.44±0.63
Present study 2.59±0.62 2.90±0.54
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hemostatic system is observed in the fibrinogen molecule. The glycation 
of fibrinogen results in the formation of a denser fibrin clot with finer 
fibers that is resistant to fibrinolysis. The glycated fibrin binds less to 
both tissue-type plasminogen activator and plasminogen and generates 
less plasmin but binds more to alpha2-antiplasmin [3,4]. In the study 
done by Madan et al. [13] and by Acang and Jalil [16] showed significant 
difference in fibrinogen levels between diabetic and healthy patients 
with increase in fibrinogen in diabetics, similar to the result obtained in 
the present study (p=0.03) (Table 9).
An acute increase in clotting Factor VII has been described during 
induced hyperglycemia in both diabetic and healthy patients [21] 
while an enhancement of thrombin activity has been shown in the 
postprandial phase in Type 2 diabetic patients; this was proportional to 
the level of hyperglycemia [22]. Postprandial hypertriglyceridemia has 
been found to precede the activation of coagulation Factor VII, and the 
degree of Factor VII activation is proportional to the increase in plasma 
triglycerides [23]. Since there is extensive evidence of important 
interactions between plasma lipoproteins and coagulation, including 
platelet aggregation and fibrinolysis [24], it seems reasonable that 
there could be an increased thrombotic tendency in the postprandial 
phase.
In the present study, changes in PT values was more significant with 
PPBS levels (p=0.04) when compared to FBS levels and APTT follows 
the same pattern with more in PPBS levels (p=0.02) and FBS levels. 
In the present study, in non-diabetes, changes in PT values were not 
significant with PPBS levels when compared to FBS levels (p=0.6) and 
APTT follows the same pattern with more in PPBS levels and FBS levels 
(p=0.1).
At present, to the best of our knowledge, there are no studies available 
in literature to compare the coagulation parameters PT, APTT in 
fasting, and postprandial state. The study done in diabetic patients 
by Temelkova-Kurktschiev et al. [25] showed significant elevation 
of fibrinogen levels in the postprandial state. In their study, the 
postprandial phase fibrinogen and PPBS were significantly associated 
(p<0.05) and the association with FBS and fibrinogen was found to be 
not significant, which was similar to the result obtained in the present 
study with PPBS showed elevated fibrinogen (p=0.001) when compared 
to FBS. The synthesis of fibrinogen, a strong risk factor for CVD in both 
diabetic and non-diabetic patients [26], increases in the postprandial 
state in diabetic patients. In controls, also, the present study showed 
elevated fibrinogen in the postprandial state (p=0.001) when compared 
to fasting state.
Limitations
Limitations Postprandial lipid profile and anti-fibrinolysis analysis 
could not be done in view of cost constraints. Another limitation was 
small sample size.
CONCLUSIONS
T2DM is a hypercoagulable state as proven by the following results 
of our study which states PT was decreased in the diabetics when 
compared to controls, APTT was decreased in diabetics when 
compared to controls, fibrinogen levels were increased in diabetics 
when compared to controls. The postprandial blood sugar levels were 
significantly associated with elevated fibrinogen levels in both diabetics 
and non-diabetics when compared to the FBS levels indicating a more 
significance association of postprandial state with hypercoagulability.
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